Diagnostic Utility in Action: Advancing Reimbursement and Integration for CNS Biomarkers
Time: 8:30 am
day: Conference Day Two
Details:
This workshop dives into the clinical and economic challenges of integrating diagnostics into CNS care pathways. With fluid and imaging biomarkers redefining eligibility for high-cost therapies, pharma and diagnostics teams must co-develop evidence plans that demonstrate payer-valued clinical utility. The session highlights how to align biomarker evidence generation with diagnostic commercialization timelines, clarify regulatory vs. payer hurdles, and build sustainable collaborations across pharma, diagnostics, and lab networks.
Key Questions Addressed:
- What level of clinical utility and economic evidence do payers require to reimburse emerging CNS diagnostics?
- How can pharma and diagnostics collaborate earlier to align biomarker development with therapeutic value demonstration?
- What infrastructure and standardization gaps must be addressed to ensure scalable diagnostic access across CNS indications?
- What types of evidence are most impactful in demonstrating diagnostic value to both clinicians and payers, and how early should this evidence be generated?
- What lessons from oncology biomarker integration can be adapted to accelerate CNS diagnostic adoption and coverage?
